Bellicum reports fda lifted clinical hold on bpx-601 phase 1/2 clinical trial

Houston, jan. 28, 2021 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the u.s. food and drug administration (fda) has lifted the clinical hold on patient enrollment and dosing in an ongoing phase 1/2 dose-escalation clinical trial evaluating bpx-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.
BLCM Ratings Summary
BLCM Quant Ranking